GlassScriptPhysician profile
Lori Delgaudio
NPI 1427093079
$1,644.51
in general payments reported to CMS, 2019-2025
23 companies · $615 in 2025
The $615 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $108 · 2021: $208 · 2022: $163 · 2023: $227 · 2024: $64.60 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $572 · Education: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.00 |
| Education | $333.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $429.17 | 2019-2025 | Orilissa, Lo Loestrin Fe, Ubrelvy |
| Astellas Pharma US INC | $372.47 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $144.40 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $101.77 | 2023-2025 | |
| Millicent US INC | $92.27 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Therapeuticsmd, INC. | $69.07 | 2019-2022 | |
| Roche Diagnostics Corporation | $63.75 | 2019-2021 | |
| Avion Pharmaceuticals | $51.67 | 2019-2020 | |
| Evofem Biosciences, INC. | $32.53 | 2021 | |
| Amag Pharmaceuticals, INC. | $29.51 | 2019 | |
| Organon LLC | $28.54 | 2022-2023 | Nexplanon |
| Axonics, INC. | $25.27 | 2024 | Axonics |
| Teleflex LLC | $24.18 | 2025 | Barrigel |
| Daiichi Sankyo INC. | $23.96 | 2019 | |
| Amgen INC. | $22.78 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $20.33 | 2022 | |
| Bioprotect Medical, INC. | $20.03 | 2025 | Bioprotect Balloon Implant System |
| Myovant Sciences INC. | $19.31 | 2022 | |
| Sumitomo Pharma America, INC. | $18.55 | 2025 | Gemtesa |
| Baxter Healthcare | $16.68 | 2021 | |
| Boston Scientific Corporation | $13.16 | 2023 | Superion Indirect Decompression System |
| Allergan, INC. | $13.09 | 2019 | |
| Merck Sharp & Dohme LLC | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Delgaudio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.